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Background: The lifetime prevalence of major depression is estimated to affect 17% of the population and is
considered the second largest health-care problem globally in terms of the number of years lived with disability.
The effects of most antidepressant treatments are poor; therefore, exercise has been assessed in a number of
randomized clinical trials. A number of reviews have previously analyzed these trials; however, none of these
reviews have addresses the effect of exercise for adults diagnosed with major depression.
Methods/design: The objective of this systematic review is to investigate the beneficial and harmful effects of
exercise, in terms of severity of depression, lack of remission, suicide, and so on, compared with treatment as usual
with or without co-interventions in randomized clinical trials involving adults with a clinical diagnosis of major
depression. A meta-analysis of the effect estimates of the individual trials, taking bias risk into consideration, will be
carried out. Any heterogeneity will be explored using meta-regression and subgroup analyses. Trial sequential
analysis will be carried out on the trials to control for risks of random errors. The results from the study will aid
health authorities and clinicians to understand whether exercise should be offered to patients with major
depression.
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Depression is a common disease affecting up to 17% of
the population during their lifetime [1]. Based on data
from the WHO, depression is thought to be the second
largest health-care problem globally, in terms of years
lived with disability (YLD) [2]. Depression is also observed
as a co-morbidity in a number of somatic diseases, signifi-
cantly contributing poorer outcomes in diseases such as
cancer, ischaemic heart disease, and diabetes. Depending
on its severity, depression is often treated using psycho-
therapy, antidepressants, or a combination of both. How-
ever, the clinical efficacy of antidepressants [3,4] and
psychotherapy [5-7] has been challenged. Both treatments
are costly in terms of time and money and may also have
adverse effects. Compliance with antidepressant treatment* Correspondence: jesper.krogh@regionh.dk
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unless otherwise stated.is poor; the dropout rate in clinical trials is reported to be
between 12% and 40% within the initial 6 to 8 weeks of
treatment [3,8].
The weakness of evidence for the beneficial effect of
treatment, along with problems related to cost, harm,
and low compliance, has resulted in an interest in using
alternative or complementary therapies. The use of exer-
cise as an intervention has attracted a lot of attention,
and various forms of exercise varying in intensity have
been assessed in a number of randomized clinical trials
to test their effectiveness as a treatment for patients with
depression.
In 2011, the authors of this paper published a meta-
analysis of randomized clinical trials examining the ef-
fect of exercise on depressive symptoms in patients with
clinical depression [9]. The results suggested that refer-
ring patients with clinical depression to exercise pro-
grams was associated with a small to moderate effect on
depressive symptoms. However, restricting the analysisThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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was non-significant. Since 2011, other reviews have been
published on the effect of exercise on depressive symp-
toms [10], in older people [11] and in patients with
chronic illnesses [12]. However, none of these reviews
addressed the specific population of adults diagnosed
with major depression according to valid diagnostic cri-
teria, such as the International Classification of Diseases
[13] or the Diagnostic and Statistical Manual of Mental
Disorders [14]. The reviews contained a number of trials
that included volunteers who were defined as being de-
pressed on the basis of psychometric testing (for ex-
ample, Beck Depression Inventory [15]), as opposed to
individuals with a clinical diagnosis of major depression.
Furthermore, several randomized clinical trials investi-
gating the effect of exercise in clinically depressed indi-
viduals have been published since our 2011 review.
Objectives
The objective of this present systematic review is to in-
vestigate the beneficial and harmful effects of exercise,
in terms of severity of depression, lack of remission,
quality of life, suicide, and so on, compared with or
without co-interventions in adults with a clinical diagno-
sis of major depression.
Apart from including new trials, the current systematic
review differs from the previous study [9]. The current
review only considers trials including participants with a
diagnosis of major depression and does not include pa-
tients referred with depressive symptoms. The harmful
effects of exercise interventions are also addressed, and
bibliographical searches have been extended to include a
Chinese and a South-American database.
Methods/design
 This systematic review will only include randomized
clinical trials. This protocol is not registered with
PROSPERO.
Inclusion criteria
 Participants should be diagnosed as having major
depression according to a valid and recognized
diagnostic system (that is, Research Diagnostic
Criteria (RDC) [16], International Classification of
Diseases (ICD) [13], or Diagnostic and Statistical
Manual of Mental disorders (DSM) [14]).
 Participants aged >17 years of both sexes.
 Randomized clinical trials. A trial is defined as a
randomized clinical trial if the allocation of
participants to intervention and comparison groups
is described as randomized (including terms such as
‘randomly’, ‘random’, and ‘randomization’). No restriction to type of publication (that is, we will
include abstracts and full text reports).
Exclusion criteria
 Trials measuring depression immediately after a
single bout of exercise.
 Trials comparing one form of exercise versus
another.
 Trials comparing different exercise intensities
without including a control group.
Interventions
 The trials had to allocate participants to an exercise
intervention versus a control group (that is, exercise
versus a control group receiving no intervention or
treatment as usual or an attention control using
light exercise) or using exercise as an add-on-
treatment (that is, exercise plus medication in the
experimental group versus medication alone in the
control group).
 Exercise intervention is defined as a systematic
physical intervention with the intention to increase
muscle strength and/or cardiovascular fitness. A
control group could include no treatment or only an
attention control using light exercise. However, it
should specifically be mentioned by the authors that
the intervention is intended to be a control
intervention. Light exercise would be equivalent to
stretching or light aerobic exercise.
Outcomes
The primary outcomes are 1) depressive symptoms mea-
sured on a continuous scale assessed at the end of the
intervention; 2) lack of remission, that is, a binary out-
come of the proportion of participants in each interven-
tion group of the trial who did not obtain remission at
the end of the intervention according to the authors’
own definition; and 3) serious adverse events defined ac-
cording to ICH-GCP as any untoward medical occur-
rence that was life threatening, resulted in death or
persistent or significant disability (ICH-GCP 1997).
Serious adverse events will accordingly include suicide
attempts as well as suicides. The secondary outcomes
are non-serious adverse events, depressive symptoms,
and lack of remission assessed beyond the intervention.
Search strategy
The search will include search CENTRAL, MEDLINE,
EMBASE, and Science Citation Index (Web of Science)
using medical subject headings (MESH or similar) when
possible and text word terms: depression, depressive dis-
order and exercise, aerobic, non-aerobic, physical activity,
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swimming, strength, and resistance. The search will also
include LILAC (Latin American and Caribbean Health
Sciences Literature) and the Chinese Wanfang database
using text word terms: depression, depressive disorder,
and exercise or physical training. The flow of trial reports
and reasons for exclusion will be presented in the
PRISMA flow chart and categorized: non-clinical popula-
tions (that is, not diagnosed according to a diagnostic sys-
tem), review or commentary, not a randomized trial, acute
exercise (that is, studies/trials investigating the effect of a
single bout of exercise), and trials including patients with
other psychiatric diagnoses (for example, bipolar). In
addition, reference lists of relevant reviews will be
searched for additional trials.
Study selection
One investigator (JK) will examine titles and abstracts to
remove obviously irrelevant reports. Two investigators
(JK + HS) will examine the remaining full text reports
determining compliance with inclusion criteria.
Data extraction
Two authors (JK, HS) will independently extract data
using a pre-piloted structured form. Any discrepancies
in the data extraction or inclusion/exclusion of trials will
be resolved by referring to the original papers. CG or
MN will assist as adjudicator in cases of disagreements.
The authors will not be blinded to article results, au-
thors, or institutions. Data extraction will, in addition to
outcomes, include information regarding country of ori-
gin, number of randomized participants, number of par-
ticipants included in efficacy analysis, mean age of
participants, diagnostic system, baseline assessment of
depression severity, type of intervention, frequency of
intervention, , duration of intervention, and recruitment
setting (clinical vs. non-clinical).
The authors JK, CG, and MN have previously pub-
lished trial reports assessing the effect of exercise in pa-
tients with depression [17,18]. To avoid academic bias, a
third assessor (CH) will assist HS in bias assessment for
these two trials.
Risk of bias assessment
Methodological studies show that trials with unclear or in-
adequate methodological quality regarding bias domains
may be associated with bias (systematic error, the overesti-
mation of benefits, and the underestimation of harms)
when compared to trials using adequate methodology
[19-24]. Definitions in the assessment of bias risk of a trial
will be done according to the Cochrane Handbook for
Systematic Reviews of Interventions [19] of the following
domains: allocation sequence generation, allocation con-
cealment, blinding of participants and personnel, blindingof outcome assessors, incomplete outcome data, selective
outcome reporting, for-profit bias, and other bias. Please
see Appendix for specifications on bias assessment.
Trials assessed as having ‘low risk of bias’ in all of the
above specified domains will be considered ‘trials with
low risk of bias’. Trials assessed as having ‘uncertain risk
of bias’ or ‘high risk of bias’ in one or more of the above
specified domains shall be considered trials with ‘high
risk of bias’. In line with our previous systematic review
[9] and the latest Cochrane review [10], trials with low
risk of bias in the allocation concealment domain,
blinded outcome assessment domain, and the intention-
to-treat analysis domain will also be characterized as tri-
als with ‘lower risk of bias.’ However, in case no or few
trials with low risk of bias will be included, we shall re-
member that the chance to know the ‘true’ intervention
effect in trials with ‘lower risk of bias’ is low or absent.
Data synthesis and analysis
In order to be able to include all of the studies in our
meta-analysis [25], estimates of standardized mean dif-
ference (SMD) for each individual study will be carried
out. SMD is the mean difference in depression score be-
tween the exercise and control groups dived by the
pooled standard deviation. The result is a unit less effect
size measure, which is comparable to other studies using
other but similar measures of outcome. By convention,
SMD effect sizes of 0.2, 0.4, and 0.8 are considered
small, medium, and large, respectively. For dichotomous
variables, we will calculate the relative risks with a 95%
confidence interval. It is expected that some trials have
several intervention groups. Data from the experimental
groups will be pooled and compared with the data from
the control group. In case of discrepancies between the
random-effects model analysis and the fixed-effect
model analysis, both results will be reported [26]; other-
wise, only results from the random-effects analysis will
be reported.
The degree of heterogeneity will be quantified using
the I-squared statistic [27], which can be interpreted as
the percentage of variation observed between the trials
attributable to between-trial differences, rather than
sampling error (chance). Heterogeneity will be explored
by analysis of sub-groups (see below).
For the primary outcomes, trial sequential analysis will
be attempted, based on mean differences or proportions
[28,29]. In order to calculate the required information size
and the cumulative Z-curve’s eventual breach of relevant
trial sequential monitoring boundaries, the required infor-
mation size for a primary continuous outcome will be
based on type I error of 5%, a beta of 10%, the standard
error of the meta-analysis, and a minimal difference of
three points on the HAM-D17. In order to calculate the
required information size and the cumulative Z-curve’s
Krogh et al. Systematic Reviews  (2015) 4:40 Page 4 of 7eventual breach of relevant trial sequential monitoring
boundaries, the required information size for the primary
dichotomous outcomes will be based on type I error of
5%, a beta of 10%, the proportion of patients in the control
group with the outcome, and a relative risk reduction of
15% or 30%. Most systematic reviews do not contain suffi-
cient power [30], and if there is no significant effect of the
intervention, it is also interesting to know whether this
represents an absence of evidence (the cumulative Z-
curve has not reached the futility area), or if it represents
evidence of an absence of effect (the cumulative Z-curve
has reached the futility area). If an absence of evidence
persists, the likely number of participants still needed to
answer the question raised can also be assessed. An inter-
esting question is whether the trial sequential monitoring
boundaries for benefit (or potentially for harms) are
crossed. This informs as to whether new trials should have
been stopped. Bayes factors will be calculated for all pri-
mary values (the ratio between the P value probability di-
vided by the probability of the meta-analysis result, given
that an anticipated intervention effect is the true effect)
[26].
To assess the potential impact of missing data (incom-
plete outcome data bias), a ‘best-worst’ case scenario will
be assessed, assuming that all participants lost to follow-
up in the intervention group had a beneficial outcome
(the group mean minus 1 standard deviation (SD)), and
all those with missing outcomes in the placebo group
have had a harmful outcome (the group mean plus 1 SD
and 2 SD). It is also planned to perform the reverse
‘worst-best-case’ scenario analysis [26].
Regarding the outcome of lack of remission, trials will
be included with incomplete or missing data. In case of
missing data for the ‘lack of remission’ outcome, missing
values will be imputed in sensitivity analysis according
to the following scenarios [31]: 1) poor outcome ana-
lysis: assuming that none of the drop-outs/participants
lost from both the experimental and the control arms
experienced the outcome, including all randomized par-
ticipants in the denominator; 2) good outcome analysis:
assuming that all of the drop-outs/participants lost from
the experimental and the control arms experienced the
outcome, including all randomized participants in the
denominator; 3) extreme case analysis favoring the ex-
perimental intervention (‘best-worse’ case scenario):
none of the drop-outs/participants lost from the experi-
mental arm, but all of the drop-outs/participants lost
from the control arm experienced the outcome, includ-
ing all randomized participants in the denominator; and
4) extreme case analysis favoring the control (‘worst-
best’ case scenario): all drop-outs/participants lost from
the experimental arm, but none from the control arm
experienced the outcome, including all randomized par-
ticipants in the denominator.Subgroup analyses
In subgroup analyses, the possible effects of a number of
variables on outcomes and heterogeneity will be com-
pared. It is expected that no, or very few, trials with low
risk of bias will be found, and therefore, an assessment
of the risk of bias by comparing trials with lower risk of
bias is planned according to adequate allocation conceal-
ment, blinded outcome assessment, and intention-to-
treat analysis to trials with high risk of bias according to
these domains. The effect of age will be assessed by
comparing trials including older participants (mean age
>60 years) with trials including younger participants
(mean age <60 years). The effect of group versus individ-
ual exercise will be assessed by comparing trials using
group exercises compared to trials using individual exer-
cises. The effect of the duration of intervention will be
assessed by comparing trials with short duration of
intervention to trials with long duration of intervention.
The two groups formed will be based on the median
duration of intervention employed. The effect of type of
control group will be assessed by comparing trials with
trials, using attention control to trials with other forms
of control. Assessment of the effect of using exercise as
an add-on therapy by comparing trials using placebo/at-
tention control/TAU as control group to trials using
antidepressant as a control group will be carried out. In
addition, a within-study comparison of low-dose exercise
versus high-dose exercise in trials using different exercise
intensities will be performed. The effect of co-morbid
somatic disease will be assessed by comparing the effect
estimates from trials including patients with depression
compared to trials including patients with depression in
addition to a somatic disease.
Publication bias will be assessed by visual inspection
of a funnel plot and by Egger’s test. The meta-analyzed
results will be presented in a summary of findings table
according to the GRADE system [32].
Discussion
In this systematic review, the assessment of the benefits
and harms of exercise interventions for adults with clin-
ical diagnosis of major depression will be reviewed. It is
intended to minimize selection bias by including biblio-
graphical databases from South America (LILACS) and
China (Wanfang) in addition to standard search strat-
egies limited to western bibliographical databases (for
example, CENTRAL, MEDLINE, EMBASE). In addition
to meta-analysis, trial sequential analysis to assess our
risks of random error is planned. The final discussion
will include an analysis of the strength and limitations of
the evidence and of the current review.
Based on the authors’ previous review and intimate
knowledge of the current subject, we expect to include
more than 1,000 patients diagnosed with depression
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view will support health-care providers and decision
makers within the health-care system on the decision to
include exercise as a standard treatment for patients
with depression.
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16. 1 OR 2 OR 3
17. 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR
12 OR 13 OR 14 OR 15
18. 16 AND 17
Appendix: Bias assessment
Allocation sequence generation
– Low risk of bias: sequence generation was achieved
using computer random number generation or a
random number table. Drawing lots, tossing a coin,
shuffling cards, and throwing dice are adequate if
performed by an independent person not otherwise
involved in the trial.
– Uncertain risk of bias: the method of sequence
generation was not specified.
– High risk of bias: the sequence generation method
was not random.
Allocation concealment
– Low risk of bias: the participant allocations could
not have been foreseen in advance of, or during,
enrolment. Allocation was controlled by a central
and independent randomization unit. The allocation
sequence was unknown to the investigators (for
example, if the allocation sequence was hidden in
sequentially numbered, opaque, and sealed envelopes).– Uncertain risk of bias: the method used to conceal
the allocation was not described so that intervention
allocations may have been foreseen in advance of, or
during, enrolment.
– High risk of bias: the allocation sequence was likely
to be known to the investigators who assigned the
participants.Blinding of participants and personnel
We do not expect this to happen in many trials, but in
case investigators have tried to blind these groups, we
will use the following:
– Low risk of bias: blinding was performed
adequately.
– Uncertain risk of bias: there was insufficient
information to assess whether blinding was likely to
induce bias on the results.
– High risk of bias: no blinding or incomplete
blinding.Blinding of outcome assessors
We do not expect this to happen in many trials, but in
case investigators have tried to blind the outcome asses-
sors, we will use the following:
– Low risk of bias: the assessment of outcomes was
not likely to be influenced by lack of blinding.
– Uncertain risk of bias: there was insufficient
information to assess whether blinding was likely to
induce bias on the results.
– High risk of bias: the assessment of outcomes was
likely to be influenced by lack of blinding.Incomplete outcome data
– Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. Suf-
ficient methods, such as multiple imputation, have
been employed to handle missing data.
– Uncertain risk of bias: there was insufficient
information to assess whether missing data in com-
bination with the method used to handle missing
data were likely to induce bias on the results.
– High risk of bias: the results were likely to be
biased due to missing data.
Analyses is considered intention to treat if missing
data is handled by adequate methods (mixed models,
multiple imputations, or similar) or if no missing data
was encountered (last observation carried forward was
considered inadequate).
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– Low risk: all predefined, or clinically relevant and
reasonably expected, outcomes are reported on. If
the original trial protocol is available, the outcomes
should be those called for in that protocol. (Note: If
the trial protocol is obtained from a trial registry
(for example, www.clinicaltrials.gov), the outcomes
to be sought are those enumerated in the original
protocol if the trial protocol was registered before
or at the time the trial has begun; if the trial
protocol was registered after the trial has begun,
those outcomes will not be considered to be
reliable in representing the outcomes initially being
sought.) If the trial protocol is not available (or if
the protocol was registered after the trial was
begun), the review authors will decide, when they
are writing the protocol for the systematic review,
what clinically relevant and reasonably expected
outcomes would be and will explicitly state those
outcomes in the pertinent methodology part of
their protocol for the systematic review.
– Unclear risk: not all predefined, or clinically
relevant and reasonably expected, outcomes are
reported fully, or it is unclear whether data on
these outcomes were recorded or not.
– High risk: one or more predefined or clinically
relevant and reasonably expected outcomes were
not reported, despite the fact that data on these
outcomes should have been likely to have been
available and even recorded.For-profit bias
– Low risk of bias: the trial appears to be free of
industry sponsorship or other type of for-profit
support that may manipulate the trial design,
conductance, or results of the trial.
– Uncertain risk of bias: the trial may or may not be
free of for-profit bias as no information on clinical
trial support or sponsorship was provided.
– High risk of bias: the trial was sponsored by industry
or received other type of for-profit support.Other bias
– Low risk of bias: the trial appears to be free of
other components (for example, academic bias) that
could put it at risk of bias.
– Uncertain risk of bias: the trial may or may not be
free of other components that could put it at risk of
bias.– High risk of bias: there are other factors in the trial
that could put it at risk of bias (for example,
baseline imbalance or academic bias).
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